Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
Stanford University · Brigham and Women's Hospital · +7 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
555
total citations
- FWCI
- 12.79
- Percentile
- 100%
- References
- 43
Citations per year
Authors
18Topics & keywords
Topics
Keywords
- Cancer immunotherapy
- Biology
- Major histocompatibility complex
- MHC class I
- Immunotherapy
- Innate immune system
- Acquired immune system
- Cell biology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.